Roivant Sciences Ltd Revenue Growth Rates (ROIV), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Roivant Sciences Ltd   (NASDAQ: ROIV)
 

ROIV's Revenue Growth by Quarter and Year

Roivant Sciences Ltd 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ROIV Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter March -
3rd Quarter December -
2nd Quarter September -
1st Quarter June 1.44
FY 1.44





ROIV Revenue first quarter 2026 Y/Y Growth Comment
Roivant Sciences Ltd reported fall in Revenue in the first quarter 2026 by -33.55% to $ 1.44 millions, from the same quarter in 2025.
The drop in the first quarter 2026 Roivant Sciences Ltd 's Revenue compares unfavorably to the Company's average Revenue jump of 43.93%.

Looking into first quarter 2026 results within Major Pharmaceutical Preparations industry 174 other companies have achieved higher Revenue growth. While Roivant Sciences Ltd ' s Revenue drop of -33.55% ranks overall at the positon no. 3695 in the first quarter 2026.


ROIV Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter March - -66.71 % -73.83 % 5.66 %
3rd Quarter December - -77.83 % -75.71 % 117.83 %
2nd Quarter September - -64.96 % -87.92 % 196.09 %
1st Quarter June -33.55 % -96.06 % 155 % 400.46 %
FY   - -89.16 % -38.94 % -

Financial Statements
Roivant Sciences Ltd 's first quarter 2026 Revenue $ 1.44 millions ROIV's Income Statement
Roivant Sciences Ltd 's first quarter 2025 Revenue $ 2.17 millions Quarterly ROIV's Income Statement


ROIV Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter March - 26 % -16.08 % -22.11 %
3rd Quarter December - 27.39 % 101.34 % 0.11 %
2nd Quarter September - -27.65 % -91.87 % 71.6 %
1st Quarter June -42.78 % -71.33 % 90.56 % -21.04 %
FY (Year on Year)   - -89.16 % -38.94 % -


Back to ROIV Growth rate Comparisons >> Back to ROIV Growth rate Comparisons >>


Revenue first quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #175
Healthcare Sector #519
Overall #3695

Revenue Y/Y Growth Statistics
High Average Low
415.63 % 43.93 % -89.16 %
(Mar 31 2022)   (Mar 31 2026)
Revenue first quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #175
Healthcare Sector #519
Overall #3695
Revenue Y/Y Growth Statistics
High Average Low
415.63 % 43.93 % -89.16 %
(Mar 31 2022)   (Mar 31 2026)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Roivant Sciences Ltd 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
334.62 % 36.6 % -91.88 %
(Dec 31 2020)  


ROIV's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2026 Roivant Sciences Ltd disclosed fall in Revenue from the fourth quarter by -42.78% to $ 1.44 millions, from $ 2.52 millions achived in the previous reporting period.

But that's not important problem, as Roivant Sciences Ltd 's Revenue generally seem to plunge in this quarter.

Within Major Pharmaceutical Preparations industry 176 other companies have achieved higher Revenue quarter on quarter growth. While Roivant Sciences Ltd 's Revenue growth quarter on quarter, overall rank is 3624.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #177
Healthcare Sector #516
Overall #3624
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #177
Healthcare Sector #516
Overall #3624
Revenue Q/Q Growth Statistics
High Average Low
334.62 % 36.6 % -91.88 %
(Dec 31 2020)  


ROIV's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2026 Roivant Sciences Ltd disclosed fall in Revenue from the fourth quarter by -42.78% to $ 1.44 millions, from $ 2.52 millions achived in the previous reporting period.

But that's not important problem, as Roivant Sciences Ltd 's Revenue generally seem to plunge in this quarter.

Within Major Pharmaceutical Preparations industry 176 other companies have achieved higher Revenue quarter on quarter growth. While Roivant Sciences Ltd 's Revenue growth quarter on quarter, overall rank is 3624.


Roivant Sciences Ltd 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 7.53 $ 8.26 $ 13.31 $ 20.33 $ 23.23
Y / Y Revenue Growth (TTM) -67.58 % -89.16 % -86.36 % -83.82 % -85.32 %
Year on Year Revenue Growth Overall Ranking # 3727 # 0 # 439 # 363 # 90
Seqeuential Revenue Change (TTM) -8.81 % -37.94 % -34.53 % -12.5 % -69.51 %
Seq. Revenue Growth (TTM) Overall Ranking # 3695 # 0 # 440 # 2109 # 373


Cumulative Revenue growth Comment
Roivant Sciences Ltd showed decline, but improvement compare to trailing twelve month Revenue decrease in Mar 31 2026. If the fiscal year would end in Jun 30 2026, Roivant Sciences Ltd 's annual Revenue drop would be -67.58% year on year to $8 millions.

In the Healthcare sector 529 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 3727.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 175
Healthcare Sector # 530
Overall # 3727

Revenue TTM Y/Y Growth Statistics
High Average Low
415.63 %
 43.93 %
-89.16 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 175
Sector # 519
S&P 500 # 3695
Cumulative Revenue growth Comment
Roivant Sciences Ltd showed decline, but improvement compare to trailing twelve month Revenue decrease in Mar 31 2026. If the fiscal year would end in Jun 30 2026, Roivant Sciences Ltd 's annual Revenue drop would be -67.58% year on year to $8 millions.

In the Healthcare sector 529 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 3727.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 175
Healthcare Sector # 530
Overall # 3727

Revenue TTM Y/Y Growth Statistics
High Average Low
415.63 %
43.93 %
-89.16 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 175
Sector # 519
S&P 500 # 3695




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
ROIV's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue drop for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Bio rad Laboratories Inc -0.05%$ -0.046 millions
Seer Inc -0.29%$ -0.289 millions
Dyadic International Inc -0.57%$ -0.568 millions
Teva Pharmaceutical Industries Limited-0.81%$ -0.814 millions
Aytu Biopharma Inc-0.91%$ -0.911 millions
Neuropace Inc -1.32%$ -1.323 millions
Ardent Health Inc -1.40%$ -1.400 millions
Sunshine Biopharma Inc -1.56%$ -1.557 millions
Pacific Biosciences Of California Inc -1.71%$ -1.706 millions
United Therapeutics Corporation-1.92%$ -1.916 millions
Orasure Technologies Inc-1.93%$ -1.930 millions
Pulmonx Corporation-1.93%$ -1.931 millions
Volitionrx Limited-1.97%$ -1.975 millions
Organon and Co -2.26%$ -2.258 millions
Airsculpt Technologies Inc -2.53%$ -2.527 millions
Charles River Laboratories International inc -2.72%$ -2.718 millions
Perrigo Company Plc-3.17%$ -3.171 millions
Zai Lab Limited-3.33%$ -3.333 millions
Vanda Pharmaceuticals Inc -3.92%$ -3.919 millions
Teladoc Health Inc -3.95%$ -3.952 millions
Dentsply Sirona Inc -4.06%$ -4.060 millions
Sanuwave Health Inc -4.18%$ -4.181 millions
Treace Medical Concepts Inc -4.24%$ -4.244 millions
Fortrea Holdings Inc -4.52%$ -4.519 millions
Positron Corporation-6.91%$ -6.907 millions
Standard Biotools Inc -7.05%$ -7.046 millions
Inspire Medical Systems inc -7.32%$ -7.316 millions
Adapthealth Corp -7.50%$ -7.505 millions
China Pharma Holdings Inc-7.55%$ -7.548 millions
Skinhealth Systems Inc -7.68%$ -7.680 millions


About Roivant Sciences Ltd Revenue Growth Rates (ROIV), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Roivant Sciences Ltd (CIK 1635088).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001635088-26-000090
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Roivant Sciences Ltd’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.